Equities research analysts expect Exelixis, Inc. (NASDAQ:EXEL) to post sales of $167.83 million for the current quarter, Zacks reports. Five analysts have made estimates for Exelixis’ earnings, with the highest sales estimate coming in at $176.86 million and the lowest estimate coming in at $151.20 million. Exelixis posted sales of $152.51 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 10%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that Exelixis will report full-year sales of $752.05 million for the current year, with estimates ranging from $717.40 million to $796.41 million. For the next financial year, analysts expect that the company will post sales of $950.78 million per share, with estimates ranging from $837.10 million to $1.12 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Exelixis.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.12. Exelixis had a net margin of 48.17% and a return on equity of 65.68%. The business had revenue of $186.10 million during the quarter, compared to the consensus estimate of $157.37 million. During the same quarter last year, the firm posted $0.06 EPS. Exelixis’s revenue was up 88.0% compared to the same quarter last year.

Several analysts recently issued reports on EXEL shares. ValuEngine raised shares of Exelixis from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price target for the company in a research report on Tuesday, July 31st. Stifel Nicolaus cut their price objective on shares of Exelixis from $30.00 to $29.00 and set a “hold” rating on the stock in a report on Thursday, May 3rd. BidaskClub raised shares of Exelixis from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 16th. Finally, Cann reaffirmed a “buy” rating and set a $40.00 price objective on shares of Exelixis in a report on Thursday, May 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $32.67.

NASDAQ EXEL traded down $0.76 during mid-day trading on Wednesday, hitting $19.64. The company’s stock had a trading volume of 4,083,900 shares, compared to its average volume of 3,728,329. Exelixis has a twelve month low of $18.50 and a twelve month high of $32.50. The company has a market cap of $6.08 billion, a P/E ratio of 39.78 and a beta of 2.02.

In other news, insider Michael Morrissey sold 234,267 shares of Exelixis stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $21.04, for a total transaction of $4,928,977.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Patrick J. Haley sold 3,663 shares of Exelixis stock in a transaction on Friday, May 18th. The stock was sold at an average price of $21.61, for a total value of $79,157.43. The disclosure for this sale can be found here. Insiders have sold a total of 827,053 shares of company stock worth $17,214,074 over the last ninety days. Insiders own 4.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in shares of Exelixis by 28.1% during the 2nd quarter. Renaissance Technologies LLC now owns 4,037,810 shares of the biotechnology company’s stock worth $86,894,000 after purchasing an additional 885,000 shares during the period. Partners Capital Investment Group LLP raised its stake in shares of Exelixis by 26.2% during the 2nd quarter. Partners Capital Investment Group LLP now owns 120,396 shares of the biotechnology company’s stock worth $2,591,000 after purchasing an additional 24,969 shares during the period. Altshuler Shaham Ltd raised its stake in shares of Exelixis by 116.5% during the 2nd quarter. Altshuler Shaham Ltd now owns 43,678 shares of the biotechnology company’s stock worth $940,000 after purchasing an additional 23,500 shares during the period. International Biotechnology Trust PLC raised its stake in shares of Exelixis by 14.5% during the 2nd quarter. International Biotechnology Trust PLC now owns 444,534 shares of the biotechnology company’s stock worth $9,566,000 after purchasing an additional 56,200 shares during the period. Finally, Stephens Investment Management Group LLC raised its stake in shares of Exelixis by 50.7% during the 2nd quarter. Stephens Investment Management Group LLC now owns 692,226 shares of the biotechnology company’s stock worth $14,675,000 after purchasing an additional 232,761 shares during the period. Institutional investors own 77.56% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.